The TNF-α inhibitor discontinuation led, in the majority of cases, to partial or total resolution of the secondary diagnosed condition; only one case was reported where despite the adverse effects, adalimumab was continued due to its high efficiency in treating the primary condition, Crohn’s disease. This evidence concerns the gene TNF and Crohn disease.